AstraZeneca's blood cancer drug meets main goal in late-stage trial

The drug, Calquence, showed meaningful improvement in patients with lymphocytic leukaemia when compared with a chemotherapy-based treatment, the company said.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news